Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSHV9C)

Drug Name
CCX-354 Drug Info
Synonyms CCX-354-C; GSK2941266
Indication
Disease Entry ICD 11 Status REF
Autoimmune diabetes 5A10 Phase 2 [1]
Rheumatoid arthritis FA20 Phase 2 [2]
Cross-matching ID
PubChem CID
135565361
CAS Number
CAS 1010073-75-2
TTD Drug ID
DMSHV9C

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 1 (CCR1) TTC24WT CCR1_HUMAN Antagonist [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
C-C chemokine receptor type 1 (CCR1) DTT CCR1 6.209 5.498 5.781 6.138
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Autoimmune diabetes
ICD Disease Classification 5A10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-C chemokine receptor type 1 (CCR1) DTT CCR1 3.93E-01 0.11 0.22
C-C chemokine receptor type 1 (CCR1) DTT CCR1 2.85E-04 0.54 0.68
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01242917) A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013 Mar;72(3):337-44.